| 产品详情 |
| Edit |   |
|---|
| Product Name | Olaparib (AZD2281) |
|---|
| Description | MW: 434.46. Background: Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively.TargetsPARP1PARP2IC505 nM1 nMIn vitroOlaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 uM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compa |
|---|
| Size | 10 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | MBS8506385 |
|---|
| Price | |
|---|
| Order / More Info | Olaparib (AZD2281) from MYBIOSOURCE INC. |
|---|
| Product Specific References | 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fi'uorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 Keith A. Menear,Claire Adcock,et al. J. Med. Chem 2008;51:6581 -6591 Menear KA, et al. J Med Chem, 2008, 51(20), 6581-6591. Evers B, et al, Clin Cancer Res, 2008, 14(12), 3916-3925. Rottenberg S, et al, Proc Natl Acad Sci U S A, 2008, 105(44), 17079-17084. Weston VJ, et al, Blood, 2010, 116(22), 4578-4587. The pharmacological and toxicological p |
|---|
| 产品资料 |
|
|